TOP > 外国特許検索 > DRUG TO PREVENT BLEEDING CAUSED BY REPERFUSION FOLLOWING ISCHEMIA

DRUG TO PREVENT BLEEDING CAUSED BY REPERFUSION FOLLOWING ISCHEMIA 新技術説明会

外国特許コード F150008472
掲載日 2015年10月26日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2014JP076117
国際公開番号 WO 2015046574
国際出願日 平成26年9月30日(2014.9.30)
国際公開日 平成27年4月2日(2015.4.2)
優先権データ
  • 特願2013-205072 (2013.9.30) JP
発明の名称 (英語) DRUG TO PREVENT BLEEDING CAUSED BY REPERFUSION FOLLOWING ISCHEMIA 新技術説明会
発明の概要(英語) A drug to prevent bleeding caused by reperfusion following ischemia, the drug comprising progranulin (PGRN).
従来技術、競合技術の概要(英語) BACKGROUND ART
Cerebral infarcts, i.e. local interruption of blood flow in the brain caused by ischemia. For acute phase cerebral infarction, anti-thrombotic agents (thrombolytic agent, anticoagulant, platelet aggregation inhibitor) used in the related art. Anti-thrombotic agents and measures for thrombus within a vessel used for the main purpose of circulation improvement. Anti-thrombotic agents include, tissue-type plasminogen activator (hereinafter, abbreviated as tPA is), urokinase (UK), heparin, argatroban, sodium ozagrel, aspirin, ticlopidine and the like are known. In particular, acute phase cerebral infarction by tissue type plasminogen activator (tPA) to thrombolytic therapy have been carried out, a certain effect is obtained.
However, or to administer large amounts of anti-thrombotic agents, anti-thrombotic drug is delayed by the side effect of cerebral hemorrhage is a deterioration in the symptoms have been reported. In particular, for this reason, anti-thrombotic agents, thrombolytic therapy with a thrombolytic agent used in particular, to reduce the side effects caused by the thrombolytic agent various proposals have been performed.
For example, Patent Document 1 (pamphlet of International Publication No. 2003/024445) is, the occurrence of side effects less frequently secure ischemia as medicament for the treatment or prevention of diseases, antithrombotic agents, anti-oxidant effects on pyrazoline -2-3 - -5 - -1 - (edaravone) phenyl methyl and the combination agent is disclosed. Patent Document 2 (Japanese Patent Application JP-2011-46685) is, over the acute phase cerebral infarction and may also be administered to a patient following a possible PRerror as a pharmaceutical composition, and thrombolytic agents, cerebral hemorrhage inhibition effect vascular endothelial growth factor (VEGF) receptor signaling and an inhibitor composition medicament for the treatment of cerebral infarction is disclosed. In addition, Patent Document 3 (Japanese Patent Application JP-2013-155167) is, ischemic brain disorders associated with cerebral hemorrhage as a medicament for preventing, 1 - (5 - isoquinolinesulfonyl) homopiperazine (fasudil) such a compound as disclosed.
On the other hand, progranulin (progranulin: sometimes referred to as PGRN) is, cell proliferation or tumor formation, wound healing, inflammation and the like known to be involved in the growth factor. The progranulin expression in the brain, neural tissue in an animal or mature differentiation of the brain involved, mutations in the gene encoding progranulin is frontotemporal dementia is one type of macular degeneration may result in a leaf and the like have been reported (non-patent document 2 and 1(Behavioural brain research 2007, Vol.185, pp.110-118) (Clinical neurology 2008, Vol.48, pp.990-993)). In addition, the non-patent document 3(Brain research 2012, Vol.1436, pp.130-136), progranulin is, over expressed in a transgenic model of progranulin study, it is possible to reduce the levels of inflammatory cytokines by act to protect against cerebral ischemia is reported. Further, the non-patent document 4(Journal of neuroinflammation 2013, Vol.10, pp.105-118), drawing the yarn in a mouse model, the quality immediately after the ischemia reperfusion is intraventricular administration of recombinant progranulin phosphoprotein, infarct size after 24, the size and improve the outcome for edema have been reported. The mechanism of migration of the neutrophils as, matrix metalloprotease 9 associated therewith, or an inflammatory cytokine tumor necrosis factor (TNF) α production decrease of the amount of pointed out. In this way, with respect to the progranulin is an ischemic vascular disease, is able to exert an anti-inflammatory effect.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NIIGATA UNIVERSITY
  • 発明者(英語)
  • SHIMOHATA, Takayoshi
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」までお問い合わせください。

PAGE TOP

close
close
close
close
close
close